XOMA Royalty

Yahoo Finance • 22 days ago

Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • 23 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Acke... Full story

Yahoo Finance • 23 days ago

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—XOMA, RMAX, GRTX, and AVNS

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the... Full story

Yahoo Finance • last month

Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • last month

Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal

Ligand Pharmaceuticals snatched up Xoma Royalty in a deal worth $739 million, the companies said Monday as both biotech stocks jumped. Continue Reading... Full story

Yahoo Finance • last month

Ligand Pharmaceuticals buying Xoma Royalty for $739 million

Ligand Pharmaceuticals agreed to acquire Xoma Royalty Corporation for $39 per share in an all-cash deal valued at about $739 million, the two companies announced April 27. The royalty aggregator model, which both companies use, involves t... Full story

Yahoo Finance • 2 months ago

XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend

* XOMA Corp - 8.375% DP PFD B (XOMAO [https://seekingalpha.com/symbol/XOMAO]) declares $0.5234/share quarterly dividend. * Forward yield [https://seekingalpha.com/symbol/XOMAO/dividends/yield?source=news_bullet] 8.23% * Payable April... Full story

Yahoo Finance • 2 months ago

XOMA Preferred Shares Series A declares $0.5391 dividend

* XOMA Preferred Shares Series A (XOMAP [https://seekingalpha.com/symbol/XOMAP]) declares $0.5391/share quarterly dividend [https://seekingalpha.com/pr/20443664-xoma-royalty-declares-quarterly-preferred-stock-dividends], * Forward yiel... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Macy's (M [https://seekingalpha.com/symbol/M]) * General Mills (GIS [https://seekingalpha.com... Full story

Yahoo Finance • 2 months ago

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

CytomX Therapeutics(NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorect... Full story

Yahoo Finance • 5 months ago

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story

Yahoo Finance • 5 months ago

XOMA Royalty Enters into Agreement to Acquire Generation Bio

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA... Full story

Yahoo Finance • 5 months ago

Huge Insider Buying in MGM and Salesforce

JasonDoiy / Getty Images As the year begins to wind down, investors are looking to position themselves for 2026. In recent days, insiders, including beneficial owners, at Crescent Biopharma Inc. (NASDAQ: CBIO), MGM Resorts International (... Full story

Yahoo Finance • 6 months ago

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the ent... Full story

Yahoo Finance • 6 months ago

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (th... Full story

Yahoo Finance • 6 months ago

Mural Oncology Announces Sanction of the Scheme by the High Court

WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Ch... Full story

Yahoo Finance • 6 months ago

Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition

(RTTNews) - Mural Oncology plc (MURA) on Wednesday announced that the final cash consideration payable to its shareholders upon closing of its acquisition by XOMA Royalty Corporation (XOMA) has been set at $2.035 per share in cash. The de... Full story

Yahoo Finance • 6 months ago

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (... Full story

Yahoo Finance • 6 months ago

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAV... Full story

Yahoo Finance • 6 months ago

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed XOMA Royalty’s acquisitions of Turns... Full story